Market closed

Affimed/$AFMD

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Ticker

$AFMD
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Mannheim, Germany

Employees

76
Website
www.affimed.com

Affimed Metrics

BasicAdvanced
$18M
-
-$4.66
2.10
-

$18M

2.1

$8.95

$1.08

484K

1.931

1.707

34.812

74.958

-23.06%

-49.42%

-149.48%

2.986

1.07

1.07

-0.217

-72.92%

-43.08%

-48.32%

1.05%

What the Analysts think about Affimed

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Affimed stock.

Affimed Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Affimed Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Affimed News

AllArticlesVideos
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

GlobeNewsWire·1 month ago
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

GlobeNewsWire·1 month ago
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AFMD

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Affimed stock?

Affimed (AFMD) has a market cap of $18M as of January 15, 2025.

What is the P/E ratio for Affimed stock?

The price to earnings (P/E) ratio for Affimed (AFMD) stock is 0 as of January 15, 2025.

Does Affimed stock pay dividends?

No, Affimed (AFMD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Affimed dividend payment date?

Affimed (AFMD) stock does not pay dividends to its shareholders.

What is the beta indicator for Affimed?

Affimed (AFMD) has a beta rating of 2.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.